Targeting Angiogenesis in Gynecologic Cancers

Behrouz Zand; Robert L. Coleman; Anil K. Sood

doi:10.1016/j.hoc.2012.01.009

Targeting Angiogenesis in Gynecologic Cancers

Behrouz Zand, Robert L. Coleman, Anil K. Sood

Gynecological Oncology & Reproductive Medicine

Research output: Contribution to journal › Review article › peer-review

13 Scopus citations

Abstract

Gynecologic malignancies carry an estimated incidence of 83,750 cases per year and estimated mortality rate of more than 27,000 women per year. New therapies and therapeutic approaches are needed to improve the outlook for women with gynecologic cancers. Recent insights at the molecular and cellular levels are paving the way for a more directed approach to target mechanisms driving tumorigenesis. This article reviews the roles of new and emerging antiangiogenesis drugs, summarizes the data obtained from clinical trials of antiangiogenic agents, and discusses trials under way to address the role of such strategies in gynecologic cancers.

Original language	English (US)
Pages (from-to)	543-563
Number of pages	21
Journal	Hematology/Oncology Clinics of North America
Volume	26
Issue number	3
DOIs	https://doi.org/10.1016/j.hoc.2012.01.009
State	Published - Jun 2012

Keywords

Angiogenesis
Antiangiogenic drugs
Bevacizumab
Gynecologic cancer

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/j.hoc.2012.01.009

Cite this

@article{5eb79977328a4d6f87fde38277ad8692,

title = "Targeting Angiogenesis in Gynecologic Cancers",

abstract = "Gynecologic malignancies carry an estimated incidence of 83,750 cases per year and estimated mortality rate of more than 27,000 women per year. New therapies and therapeutic approaches are needed to improve the outlook for women with gynecologic cancers. Recent insights at the molecular and cellular levels are paving the way for a more directed approach to target mechanisms driving tumorigenesis. This article reviews the roles of new and emerging antiangiogenesis drugs, summarizes the data obtained from clinical trials of antiangiogenic agents, and discusses trials under way to address the role of such strategies in gynecologic cancers.",

keywords = "Angiogenesis, Antiangiogenic drugs, Bevacizumab, Gynecologic cancer",

author = "Behrouz Zand and Coleman, {Robert L.} and Sood, {Anil K.}",

note = "Funding Information: Behrouz Zand is supported by NCI-DHHS-NIH T32 Training Grant ( T32 CA101642 ). Portions of this work were supported by the Gynecologic Cancer Foundation , the National Institutes of Health ( CA 109298, P50 CA083639, P50 CA098258, CA128797, RC2GM092599, and U54 CA151668 ), the Ovarian Cancer Research Fund, Inc . (Program Project Development Grant), the DOD ( OC073399, W81XWH-10-1-0158, and BC085265 ), Baylor College of Medicine and the MD Anderson Cancer Center Multidisciplinary Research Program, the Zarrow Foundation, the Marcus Foundation, the Blanton-Davis Ovarian Cancer Research Program, the Laura and John Arnold Foundation, the RGK Foundation, and the Betty Ann Asche Murray Distinguished Professorship. ",

year = "2012",

month = jun,

doi = "10.1016/j.hoc.2012.01.009",

language = "English (US)",

volume = "26",

pages = "543--563",

journal = "Hematology/Oncology Clinics of North America",

issn = "0889-8588",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Targeting Angiogenesis in Gynecologic Cancers

AU - Zand, Behrouz

AU - Coleman, Robert L.

AU - Sood, Anil K.

N1 - Funding Information: Behrouz Zand is supported by NCI-DHHS-NIH T32 Training Grant ( T32 CA101642 ). Portions of this work were supported by the Gynecologic Cancer Foundation , the National Institutes of Health ( CA 109298, P50 CA083639, P50 CA098258, CA128797, RC2GM092599, and U54 CA151668 ), the Ovarian Cancer Research Fund, Inc . (Program Project Development Grant), the DOD ( OC073399, W81XWH-10-1-0158, and BC085265 ), Baylor College of Medicine and the MD Anderson Cancer Center Multidisciplinary Research Program, the Zarrow Foundation, the Marcus Foundation, the Blanton-Davis Ovarian Cancer Research Program, the Laura and John Arnold Foundation, the RGK Foundation, and the Betty Ann Asche Murray Distinguished Professorship.

PY - 2012/6

Y1 - 2012/6

N2 - Gynecologic malignancies carry an estimated incidence of 83,750 cases per year and estimated mortality rate of more than 27,000 women per year. New therapies and therapeutic approaches are needed to improve the outlook for women with gynecologic cancers. Recent insights at the molecular and cellular levels are paving the way for a more directed approach to target mechanisms driving tumorigenesis. This article reviews the roles of new and emerging antiangiogenesis drugs, summarizes the data obtained from clinical trials of antiangiogenic agents, and discusses trials under way to address the role of such strategies in gynecologic cancers.

AB - Gynecologic malignancies carry an estimated incidence of 83,750 cases per year and estimated mortality rate of more than 27,000 women per year. New therapies and therapeutic approaches are needed to improve the outlook for women with gynecologic cancers. Recent insights at the molecular and cellular levels are paving the way for a more directed approach to target mechanisms driving tumorigenesis. This article reviews the roles of new and emerging antiangiogenesis drugs, summarizes the data obtained from clinical trials of antiangiogenic agents, and discusses trials under way to address the role of such strategies in gynecologic cancers.

KW - Angiogenesis

KW - Antiangiogenic drugs

KW - Bevacizumab

KW - Gynecologic cancer

UR - http://www.scopus.com/inward/record.url?scp=84859998680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859998680&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2012.01.009

DO - 10.1016/j.hoc.2012.01.009

M3 - Review article

C2 - 22520979

AN - SCOPUS:84859998680

SN - 0889-8588

VL - 26

SP - 543

EP - 563

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

IS - 3

ER -

Targeting Angiogenesis in Gynecologic Cancers

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this